The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis - Definition, Clinical Presentation and Diagnosis
- PMID: 38423918
- DOI: 10.1016/j.dld.2024.02.005
The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis - Definition, Clinical Presentation and Diagnosis
Abstract
Eosinophilic esophagitis (EoE) is a chronic type 2-mediated inflammatory disease of the esophagus that represents the most common eosinophilic gastrointestinal disease. Experts in the field of EoE across Italy (i.e., EoETALY Consensus Group) including gastroenterologists, endoscopists, allergologists/immunologists, and paediatricians conducted a Delphi process to develop updated consensus statements for the management of patients with EoE and update the previous position paper of the Italian Society of Gastroenterology (SIGE) in light of recent evidence. Grading of the strength and quality of the evidence of the recommendations was performed using accepted GRADE criteria. The guideline is divided in two documents: Part 1 includes three chapters, namely 1) definition, epidemiology, and pathogenesis; 2) clinical presentation and natural history, and 3) diagnosis, while Part 2 includes two chapters: 4) treatment and 5) monitoring and follow-up. This document has received the endorsement of three Italian national societies including the SIGE, the Italian Society of Neurogastroenterology and Motility (SINGEM), and the Italian Society of Allergology, Asthma, and Clinical Immunology (SIAAIC). With regards to patients' involvement, these guidelines involved the contribution of members of ESEO Italia, the Italian Association of Families Against EoE.
Keywords: EoE; EoETALY; Eosinophilic esophagitis; Guidelines.
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest Nicola de Bortoli: Advisory board member for: AlfaSigma, Sanofi Genzyme, Dr Falk; Lecture grants from Reckitt-Benkiser, Malesci, Dr. Flak, Sofar, Alfa-Sigma, Pharma-Line. Pierfrancesco Visaggi: Has served as speaker for Dr Falk, JB Pharmaceuticals, Malesci. Roberto Penagini: Has served as speaker for Dr Falk, Sanofi. Edda Battaglia: has served as consultant for NZP, GUNA Gaia Pellegatta has served as speaker for Dr Falk, Sanofi Genzyme, Malesci. Paola Iovino: Has served as consultant for Dr Falk Giovanni Marasco: Served as an advisory board member for AlfaSigma, EG Pharma, Monteresearch srl, Recordati, Cineca. Received lecture grants from Agave, AlfaSigma, Bromatech, Clorofilla, Echosens, Ferring, Mayoly Spindler, Menarini and Schwabe Pharma. Salvatore Oliva: Has served as speaker for Sanofi, Medtronic; Has served as consultant for: Sanofi, Medtronic, Brystol; Has received research support from Alfa Sigma, Medtronic. Francesca Racca: has served as speaker for Sanofi; has served as consultant for Dr Falk, Sanofi, GSK Erminia Ridolo: has served as consultant for Dr Falk Edoardo Vincenzo Savarino: has served as speaker for Abbvie, Agave, AGPharma, Alfasigma, Aurora Pharma, CaDiGroup, Celltrion, Dr Falk, EG Stada Group, Fenix Pharma, Fresenius Kabi, Galapagos, Janssen, JB Pharmaceuticals, Innovamedica/Adacyte, Malesci, Mayoly Biohealth, Omega Pharma, Pfizer, Reckitt Benckiser, Sandoz, SILA, Sofar, Takeda, Tillots, Unifarco; has served as consultant for Abbvie, Agave, Alfasigma, Biogen, Bristol-Myers Squibb, Celltrion, Diadema Farmaceutici, Dr. Falk, Fenix Pharma, Fresenius Kabi, Janssen, JB Pharmaceuticals, Merck & Co, Nestlè, Reckitt Benckiser, Regeneron, Sanofi, SILA, Sofar, Synformulas GmbH, Tssakeda, Unifarco; he received research support from Pfizer, Reckitt Benckiser, SILA, Sofar, Unifarco, Zeta Farmaceutici. Bruno Annibale, Federica Baiano Svizzero, Giovanni Barbara, Brigida Barberio, Ottavia Bartolo, Antonio Di Sabatino, Ludovico Docimo, Marzio Frazzoni, Manuele Furnari, Matteo Ghisa, Andrea Iori, Marco Vincenzo Lenti, Elisa Marabotto, Aurelio Mauro, Marcella Pesce, Antonino Carlo Privitera, Ilaria Puxeddu, Mentore Ribolsi, Salvatore Russo, Giovanni Sarnelli, Salvatore Tolone, Patrizia Zentilin, Fabiana Zingone: None.
Similar articles
-
The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis-Current Treatment and Monitoring.Dig Liver Dis. 2024 Jul;56(7):1173-1184. doi: 10.1016/j.dld.2024.02.020. Epub 2024 Mar 22. Dig Liver Dis. 2024. PMID: 38521670
-
Diagnosis and management of eosinophilic esophagitis in children: An update from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN).J Pediatr Gastroenterol Nutr. 2024 Aug;79(2):394-437. doi: 10.1002/jpn3.12188. Epub 2024 Jun 24. J Pediatr Gastroenterol Nutr. 2024. PMID: 38923067 Review.
-
Joint ESPGHAN/NASPGHAN Guidelines on Childhood Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis.J Pediatr Gastroenterol Nutr. 2024 Jan;78(1):122-152. doi: 10.1097/MPG.0000000000003877. Epub 2023 Jul 4. J Pediatr Gastroenterol Nutr. 2024. PMID: 38291684
-
British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults.Gut. 2022 Aug;71(8):1459-1487. doi: 10.1136/gutjnl-2022-327326. Epub 2022 May 23. Gut. 2022. PMID: 35606089 Free PMC article.
-
Eosinophilic esophagitis: Update in diagnosis and management. Position paper by the Italian Society of Gastroenterology and Gastrointestinal Endoscopy (SIGE).Dig Liver Dis. 2017 Mar;49(3):254-260. doi: 10.1016/j.dld.2016.11.012. Epub 2016 Dec 2. Dig Liver Dis. 2017. PMID: 27979389 Review.
Cited by
-
The Dynamic Evolution of Eosinophilic Esophagitis.Diagnostics (Basel). 2025 Jan 21;15(3):240. doi: 10.3390/diagnostics15030240. Diagnostics (Basel). 2025. PMID: 39941170 Free PMC article. Review.
-
Optimal Assessment, Treatment, and Monitoring of Adults with Eosinophilic Esophagitis: Strategies to Improve Outcomes.Immunotargets Ther. 2024 Jul 24;13:367-383. doi: 10.2147/ITT.S276869. eCollection 2024. Immunotargets Ther. 2024. PMID: 39071859 Free PMC article. Review.
-
The clinical impact of conventional therapies for adults and adolescents suffering from eosinophilic esophagitis, a type 2 inflammatory chronic disease, and their economic consequences in Italy: Systematic literature review and meta-analysis.J Allergy Clin Immunol Glob. 2024 Dec 11;4(1):100383. doi: 10.1016/j.jacig.2024.100383. eCollection 2025 Feb. J Allergy Clin Immunol Glob. 2024. PMID: 39877128 Free PMC article.
-
Eosinophilic Esophagitis and Cow's Milk: Mechanisms, Challenges, and Treatment Perspectives.Nutrients. 2025 Jan 12;17(2):265. doi: 10.3390/nu17020265. Nutrients. 2025. PMID: 39861395 Free PMC article. Review.
-
Eosinophilic esophagitis in children and adolescents: a clinical practice guideline.Ital J Pediatr. 2025 Jul 23;51(1):242. doi: 10.1186/s13052-025-02056-x. Ital J Pediatr. 2025. PMID: 40702503 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical